Summit Therapeutics PLC Total Assets
Summit Therapeutics PLC total assets. Based on the latest financial reports, Summit Therapeutics PLC (SMMT) holds total assets worth $752.18 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Summit Therapeutics PLC (SMMT) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Summit Therapeutics PLC (2003–2025)
Total assets of Summit Therapeutics PLC from 2003 to 2025. This chart illustrates how Summit Therapeutics PLC's total assets have evolved over time, based on quarterly financial data. See SMMT stock price and chart for real-time trading data and today's change.
Summit Therapeutics PLC - Asset Composition Analysis
Summit Therapeutics PLC Total Assets Breakdown (December 2025)
Summit Therapeutics PLC total assets breakdown as of December 2025. Summit Therapeutics PLC's total assets of $752.18 Million consist of 95.9% current assets and 4.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 30.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $1.49 Million | 0.3% |
Asset Composition Trend (2003–2025)
This chart illustrates how Summit Therapeutics PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore SMMT working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Summit Therapeutics PLC's current assets represent 95.9% of total assets in 2025, a decrease from 100.0% in 2003.
- Cash Position: Cash and equivalents constituted 30.0% of total assets in 2025, down from 100.0% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 25.0% in 2003.
- Asset Diversification: The largest asset category is goodwill at 0.3% of total assets.
Summit Therapeutics PLC Competitors by Total Assets
Key competitors of Summit Therapeutics PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Summit Therapeutics PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.96 | 3.80 | 4.49 |
| Quick Ratio | 6.96 | 3.80 | 3.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $617.01 Million | $134.95 Million | $58.79 Million |
Summit Therapeutics PLC - Advanced Valuation Insights
This section examines the relationship between Summit Therapeutics PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 21.88 |
| Latest Market Cap to Assets Ratio | 22.61 |
| Asset Growth Rate (YoY) | 60.2% |
| Total Assets | $557.50 Million |
| Market Capitalization | $12.60 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Summit Therapeutics PLC's assets at a significant premium (22.61x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Summit Therapeutics PLC's assets grew by 60.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Summit Therapeutics PLC (2003–2025)
The table below shows the annual total assets of Summit Therapeutics PLC from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $557.50 Million | +60.18% |
| 2024-12-31 | $348.05 Million | +116.71% |
| 2023-12-31 | $160.60 Million | -70.34% |
| 2022-12-31 | $541.43 Million | +544.24% |
| 2021-12-31 | $84.04 Million | +11.63% |
| 2020-12-31 | $75.29 Million | -0.23% |
| 2019-12-31 | $75.46 Million | -5.12% |
| 2018-12-31 | $79.53 Million | +4.12% |
| 2017-12-31 | $76.38 Million | +62.58% |
| 2016-12-31 | $46.98 Million | +31.55% |
| 2015-12-31 | $35.71 Million | +22.20% |
| 2014-12-31 | $29.22 Million | +142.86% |
| 2013-12-31 | $12.03 Million | +74.05% |
| 2012-12-31 | $6.91 Million | +13.00% |
| 2011-12-31 | $6.12 Million | -24.06% |
| 2010-12-31 | $8.06 Million | -56.16% |
| 2009-12-31 | $18.38 Million | -8.54% |
| 2008-12-31 | $20.09 Million | -71.04% |
| 2007-12-31 | $69.38 Million | +49.40% |
| 2006-12-31 | $46.44 Million | +79.53% |
| 2005-12-31 | $25.87 Million | -3.76% |
| 2004-12-31 | $26.88 Million | +18314.66% |
| 2003-12-31 | $145.96K | -- |
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cance… Read more